Johnson & Johnson (J&J) and Protagonist Therapeutics’s joint interleukin-23 (IL-23) inhibitor, icotrokinra, has met the primary endpoint in a Phase IIb study in patients with moderately to ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Patients with fingernail psoriasis who were super responders had greater rates of fingernail clearance following 68 weeks of guselkumab treatment than patients with fingernail psoriasis who were not ...

ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Cases of angioedema and urticaria ...

The study cohort included 338 patients on tildrakizumab, 14,621 on risankizumab, 10,824 on guselkumab, and 5,738 on ustekinumab, with a mean (SD) age ranging from 46.6 (12.7) to 48.5 (14.2 ...

Credit: Getty Images Guselkumab is a promising treatment option for patients ... The array of other biologics used to treat psoriasis includes risankizumab, brodalumab, secukinumab, ixekizumab, and ...

A Phase 2b/3, randomised, double-blind, placebo-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ...

New Delhi: Pharmaceutical major Sun Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and ...